Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment ofchronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Epistemonikos ID: ba688917e729e0e4d74909b31035a7505242c10e
First added on: Jun 27, 2026